Alembic Pharma Financial Statements

Alembic Pharma (APLLTD) reported revenue of ₹73.45B in FY2026 with net income of ₹6.75B. Total assets stood at ₹87.63B. Net worth was ₹56.75B (₹5,675 Cr) and free cash flow was ₹3.48B.

Alembic Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		66.72B	73.45B
Cost of Rev. Cost of Revenue		-17.93B	-19.84B
Gross Profit		48.79B	53.60B
SGA Sales, General & Admin		-38.70B	-17.32B
Op. Income Operating Income		7.30B	7.33B
PBT Profit Before Tax		7.06B	6.94B
Net Income		5.82B	6.75B
Dil. Shares Diluted Shares		196.57M	196.55M
Diluted EPS		29.68	34.33

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Alembic Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Alembic Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		40.88B	45.43B
Non-curr. assets Total non-current assets		36.85B	42.20B
Total assets		77.73B	87.63B
Curr. liabilities Total current liabilities		24.12B	25.94B
Non-curr. liab. Total non-current liabilities		1.71B	5.00B
Total liabilities		25.83B	30.94B
Total equity		51.90B	56.69B
Total liab. & eq. Total liabilities & equity		77.73B	87.63B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Alembic Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Alembic Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		7.07B	6.94B
Operating CF Cash flow Operating Activities		879.70M	7.83B
Capex Investments in PPE		-5.64B	-4.35B
Investing CF Cash flow Investing Activities		-5.68B	-5.06B
Dividend Paid		-2.16B	-2.16B
Financing CF Cash flow Financing Activities		4.44B	-1.64B
Cash (start) Cash at beginning of period		1.20B	834.80M
Cash (end) Cash at end of period		834.80M	1.96B
FCF Free Cash Flow		-4.76B	3.48B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Alembic Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026